RTW Biotech Opportunities has an additional market quote in sterling.
Overview
Performance
Portfolio
Dividends
Charges
Gearing
Research
Announcements
Management
Documents
Invest
Engage
Data as at: 25/04/2024
In
Objective
To achieve positive absolute performance and superior long-term capital appreciation, with a focus on forming, building, and supporting world-class life sciences, biopharmaceutical and medical technology companies.
AIC sector
Management group
RTW Investments
Company website
Launch date
29/10/2019
December
Domicile
Guernsey
Fund manager
Naveen Yalamanchi, Roderick Wong, Stephanie Sirota, Sabera Loughran
Dividend frequency
Data Not Available
Wind-up provisions
The Company has an unlimited life.
Market Cap (m) | Total assets (m) | Price (last close) | NAV | Discount / premium (%) | Gearing (%) | Dividend yield (%) | Dividend dates | Ongoing charge (%) |
---|---|---|---|---|---|---|---|---|
510.24 | 750.92 | 1.33 | 1.95 | -32.05 | 0 | 0.00 | N/A | 1.87 (31/12/2023) |
Scroll
Note
Dividends
Dividends declared in last 12 months
There have been no dividends in the last 12 months.
Performance (%)
Return type | 1 year | 3 years | 5 years | 10 years | |
---|---|---|---|---|---|
RTW Biotech Opportunities | Share price total return | 10.2 | -35.7 | N/A | N/A |
Biotechnology & Healthcare AIC sector | Share price total return | -3.0 | -21.1 | 2.5 | 129.2 |
Scroll
Share structure
Number of shares
385,086,512
9,203,791
Traded volumes (number of shares)
Yesterday | 1 month | 1 year | 5 years | |
---|---|---|---|---|
Total | 726,443 | 9,561,799 | 90,774,915 | 0 |
Average | N/A | 472,134 | 361,665 | 0 |
Scroll
Traded values (m)
Yesterday | 1 month | 1 year | 5 years | |
---|---|---|---|---|
Total | 0.96 | 12.52 | 117.38 | 0 |
Average | N/A | 0.62 | 0.47 | 0 |
Scroll
Trading details
Top holdings
Data as at : 30/06/2022
Investment | % of total assets |
---|---|
Other Assets And Liabilities | 28.5 |
Rocket | 10.3 |
Ji Xing | 7.7 |
Equity Swaps | 5.9 |
Rtw Royalty Holdings 2 | 4.6 |
Prometheus Biosciences | 4.2 |
Immunocore | 3.8 |
Avidity | 3.2 |
Beta Bionics | 1.8 |
Ni Kang | 1.4 |
Data provided by Morningstar.
Company documents provided by FE fundinfo.